CF PharmTech repurchases 14,500 H-shares; outstanding share count dips 0.0048%

Bulletin Express06-10 19:05

CF PharmTech, Inc. reported a further share buyback on 10 June 2026, purchasing 14,500 H-shares on the Hong Kong Stock Exchange at prices between HK$18.10 and HK$18.34, with a volume-weighted average cost of HK$18.2369 per share. The aggregate consideration amounted to HK$0.26 million.

Following the transaction, the company’s issued share base (excluding treasury shares) fell from 300.92 million to 300.91 million, a marginal decrease of 0.0048%. Treasury shares rose to 1.31 million, while the total number of issued shares remained unchanged at 302.22 million.

The repurchase forms part of the mandate approved on 16 December 2025, which allows buybacks of up to 30.22 million shares. To date, CF PharmTech has repurchased 1.31 million shares under this authority, representing 0.43% of the shares outstanding on the mandate date. All repurchased shares to date have been retained as treasury stock.

Pursuant to Hong Kong listing rules, the company is now subject to a 30-day moratorium—until 10 July 2026—on issuing new shares or selling treasury shares. Management confirmed that the repurchase complied with all applicable regulations and that no repurchased shares have been cancelled as of the disclosure date.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120748460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120748460","market":"us","top_or_hot":-1,"title":"CF PharmTech repurchases 14,500 H-shares; outstanding share count dips 0.0048%","media":"Bulletin Express","content":"<p>CF PharmTech, Inc. reported a further share buyback on 10 June 2026, purchasing 14,500 H-shares on the Hong Kong Stock Exchange at prices between HK$18.10 and HK$18.34, with a volume-weighted average cost of HK$18.2369 per share. The aggregate consideration amounted to HK$0.26 million.</p>\n<p>Following the transaction, the company’s issued share base (excluding treasury shares) fell from 300.92 million to 300.91 million, a marginal decrease of 0.0048%. Treasury shares rose to 1.31 million, while the total number of issued shares remained unchanged at 302.22 million.</p>\n<p>The repurchase forms part of the mandate approved on 16 December 2025, which allows buybacks of up to 30.22 million shares. To date, CF PharmTech has repurchased 1.31 million shares under this authority, representing 0.43% of the shares outstanding on the mandate date. All repurchased shares to date have been retained as treasury stock.</p>\n<p>Pursuant to Hong Kong listing rules, the company is now subject to a 30-day moratorium—until 10 July 2026—on issuing new shares or selling treasury shares. Management confirmed that the repurchase complied with all applicable regulations and that no repurchased shares have been cancelled as of the disclosure date.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech repurchases 14,500 H-shares; outstanding share count dips 0.0048%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech repurchases 14,500 H-shares; outstanding share count dips 0.0048%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-10 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PharmTech, Inc. reported a further share buyback on 10 June 2026, purchasing 14,500 H-shares on the Hong Kong Stock Exchange at prices between HK$18.10 and HK$18.34, with a volume-weighted average cost of HK$18.2369 per share. The aggregate consideration amounted to HK$0.26 million.</p>\n<p>Following the transaction, the company’s issued share base (excluding treasury shares) fell from 300.92 million to 300.91 million, a marginal decrease of 0.0048%. Treasury shares rose to 1.31 million, while the total number of issued shares remained unchanged at 302.22 million.</p>\n<p>The repurchase forms part of the mandate approved on 16 December 2025, which allows buybacks of up to 30.22 million shares. To date, CF PharmTech has repurchased 1.31 million shares under this authority, representing 0.43% of the shares outstanding on the mandate date. All repurchased shares to date have been retained as treasury stock.</p>\n<p>Pursuant to Hong Kong listing rules, the company is now subject to a 30-day moratorium—until 10 July 2026—on issuing new shares or selling treasury shares. Management confirmed that the repurchase complied with all applicable regulations and that no repurchased shares have been cancelled as of the disclosure date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1120748460","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120748460","pubTimestamp":1781089538,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CF PharmTech, Inc. reported a further share buyback on 10 June 2026, purchasing 14,500 H-shares on the Hong Kong Stock Exchange at prices between HK$18.10 and HK$18.34, with a volume-weighted average...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PharmTech回购14,500股H股；流通股数量下降0.0048%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PharmTech, Inc. reported a further share buyback on 10 June 2026, purchasing 14,500 H-shares on the Hong Kong Stock Exchange at prices between HK$18.10 and HK$18.34, with a volume-weighted average cost of HK$18.2369 per share. The aggregate consideration amounted to HK$0.26 million.\nFollowing the transaction, the company’s issued share base (excluding treasury shares) fell from 300.92 million to 300.91 million, a marginal decrease of 0.0048%. Treasury shares rose to 1.31 million, while the total number of issued shares remained unchanged at 302.22 million.\nThe repurchase forms part of the mandate approved on 16 December 2025, which allows buybacks of up to 30.22 million shares. To date, CF PharmTech has repurchased 1.31 million shares under this authority, representing 0.43% of the shares outstanding on the mandate date. All repurchased shares to date have been retained as treasury stock.\nPursuant to Hong Kong listing rules, the company is now subject to a 30-day moratorium—until 10 July 2026—on issuing new shares or selling treasury shares. Management confirmed that the repurchase complied with all applicable regulations and that no repurchased shares have been cancelled as of the disclosure date.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120748460","isCrawlerRequest":true}